Table 4. Efficacy: arm A: DG followed by erlotinib if progression, arm B: erlotinib followed by DG if progression.
| Arm A (n=48) | Arm B (n=51) | |
|---|---|---|
| Time to second progression (months) | 7.5±3.6 | 5.8±2.2 |
| Time to first progression (months) | 4.7±2 | 2.7±1.5 |
| Follow-up (median, months) | 9.4±4.2 | 7.1±2.2 |
| Objective responses (first line) | ||
| Not assessable (%) | 10 (20.8) | 3 (5.9) |
| Stable (%) | 16 (33.3) | 16 (31.4) |
| Progression (%) | 12 (25.0) | 23 (45.1) |
| Partial response (%) | 10 (20.8) | 9 (17.6) |
| Complete response (%) | 0 (0.0) | 0 (0.0) |
| Objective responses (second line) | ||
| Not assessable (%) | 22 (45.8) | 30 (58.8) |
| Stable (%) | 9 (18.8) | 8 (15.7) |
| Progression (%) | 14 (29.20) | 7 (13.7) |
| Partial response (%) | 3 (6.3) | 6 (11.8) |
| Complete response (%) | 0 (0.0) | 0 (0.0) |
Abbreviation: DG=docetaxel and gemcitabine.